ARTL on XNAS, Health Care, Artelo Biosciences, Inc., job postings
Measures activity, not value. Not investment advice.
Shares down 97% in a year while cash is just $4K against an annual loss of $11.3M.
WatchNews at 5.0 times its usual week over 7 days
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $1.8M.
30 Nov 2021RevenueNet incomeNet losstallest bar $4.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$1.8M
30 Jun 2026
–
-$2.4M
31 Mar 2026
–
-$3.0M
31 Dec 2025
–
-$4.2M
30 Sep 2025
–
-$3.1M
30 Jun 2025
–
-$3.2M
31 Mar 2025
–
-$2.4M
31 Dec 2024
–
-$3.8M
30 Sep 2024
–
-$1.1M
30 Jun 2024
–
-$2.4M
31 Mar 2024
–
-$2.5M
31 Dec 2023
–
-$3.1M
30 Sep 2023
–
-$2.4M
30 Jun 2023
–
-$1.6M
31 Mar 2023
–
-$2.2M
31 Dec 2022
–
-$3.3M
30 Sep 2022
–
-$2.3M
30 Jun 2022
–
-$2.4M
31 Mar 2022
–
-$2.0M
31 Dec 2021
–
-$3.2M
30 Nov 2021
–
-$2.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$11.3M
-$12.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$4K
$1.7M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$875K
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
-$845K
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$6.65
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.21
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
–
No data for this company
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
3.2%
30K shares held by 13F filers (30 Sep 2026) of 937K outstanding (11 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.0%
28K shares sold short (30 Oct 2026) of 937K outstanding (11 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.0
28K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-20%
35K shares sold short in the report before, 28K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
48%
48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
5
5 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.0×
5 articles in the last 7 days; its usual week has 1.
Price $1.39 on 20 Nov 2026, -97% over 12 months (12-month range $1.39 to $94.86)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).Institutional holders (13F filers). 8 13F filers reported holding it in the latest 13F quarter, -11% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is total debt at period end: short- and long-term borrowings at $470K (31 Mar 2026), higher than 88% of its own history.
had 875K shares sold short in the 15 Apr 2025 report, 144× the same report last year.
Same report last year: 6,082; its normal report is 14K.
See the evidence
This period
875K (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
14K
Typical spread (median absolute deviation)
11K
How far from its usual level
+17.2
Same report last year
6,082
History used
2,511 days
the 15 Apr 2025 report24 earlier reportsnormal: 14K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.8M shares sold short in the 15 Apr 2021 report, 97× the same report last year.
Same report last year: 19K; its normal report is 235K.
See the evidence
This period
1.8M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
235K
Typical spread (median absolute deviation)
230K
How far from its usual level
+4.7
Same report last year
19K
History used
1,050 days
the 15 Apr 2021 report24 earlier reportsnormal: 235K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 101 entries; narrow the window or the kind of data to see older ones.
Not listed: 108 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001621221
Ticker
ARTL
Domain
artelobio.com
Hq location
CA|SOLANA BEACH|92075 (1 unverified)
Name
Artelo Biosciences, Inc., KNIGHT KNOX DEVELOPMENT CORP., REACTIVE MEDICAL INC.
SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)175 records14 Jan 2016 to 12 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)581 data points28 Feb 2014 to 11 Nov 2026
SEC Form 4 insider transactions10 records, 36 data points11 Oct 2019 to 12 Aug 2022
FINRA short interest (twice monthly)544 data points31 May 2018 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3716 data points21 Jun 2019 to 20 Nov 2026